One-Year Outcomes of Patients With Established Coronary Artery Disease Presenting With Acute Coronary Syndromes.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 27 11 2018
revised: 23 01 2019
accepted: 31 01 2019
pubmed: 25 2 2019
medline: 21 1 2020
entrez: 25 2 2019
Statut: ppublish

Résumé

The risk of major adverse cardiovascular events (MACE) remains high in patients with established coronary artery disease (CAD). The aim of this study was to assess the prognostic significance of established CAD in patients who present with acute coronary syndromes (ACS) using a large established multicenter registry. Consecutive patients from the Melbourne Interventional Group registry who presented with ACS and underwent percutaneous coronary intervention from 2005 to 2015 were included. Patients with a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass graft surgery were included in the established CAD cohort. The primary end points were 12-month mortality and 12-month MACE. Of the 12,878 ACS patients included in our study, 3,542 (28%) patients had established CAD. Over the 10-year study period, the proportion of patients presenting with established CAD decreased (30.7% to 25.2%; p-for-overall-trend <0.001). Non-ST elevation myocardial infarction was the most prominent presentation in the established CAD cohort (45.1%) whereas ST-elevation myocardial infarction was the most prominent in the de novo CAD cohort (51%; p< 0.001). The patients in the established CAD cohort were older, had more co-morbidities and were more likely to present with high-risk features such as atrial fibrillation, left main disease, multivessel CAD and left ventricular dysfunction (all p < 0.001). Regarding revascularization in ST-elevation myocardial infarction presentations, symptom-to-door time was shorter, whereas door-to-balloon-time was longer in those with established CAD (p < 0.001). On multivariate analysis, established CAD was an independent risk factor for 12-month MACE (odds ratio 1.40, 95% confidence intervals 1.23 to 1.58, p < 0.001), but not for 12-month mortality (odds ratio 1.08, 95% confidence intervals 0.77 to 1.52, p = 0.66). In conclusion, patients with a history of myocardial infarction or previous revascularization have a higher rate of MACE at 12 months. Despite this they do not appear to suffer from higher mortality.

Identifiants

pubmed: 30797559
pii: S0002-9149(19)30164-X
doi: 10.1016/j.amjcard.2019.01.037
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1387-1392

Informations de copyright

Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Auteurs

Alexandra Murphy (A)

Department of Cardiology, Austin Health, Melbourne, Australia.

Garry Hamilton (G)

Department of Cardiology, Austin Health, Melbourne, Australia.

Nick Andrianopoulos (N)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia.

Matias B Yudi (MB)

Department of Cardiology, Austin Health, Melbourne, Australia; University of Melbourne, Melbourne, Australia.

Omar Farouque (O)

Department of Cardiology, Austin Health, Melbourne, Australia; University of Melbourne, Melbourne, Australia.

Stephen J Duffy (SJ)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia; Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia.

Jeffrey Lefkovits (J)

Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia.

Angela Brennan (A)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia.

Christopher M Reid (CM)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia; School of Public Health, Curtin University, Perth, Western Australia.

Andrew E Ajani (AE)

Centre of Cardiovascular Research and Education in Therapeutics (CCRE), Monash University, Melbourne, Australia; University of Melbourne, Melbourne, Australia; School of Public Health, Curtin University, Perth, Western Australia.

David J Clark (DJ)

Department of Cardiology, Austin Health, Melbourne, Australia; University of Melbourne, Melbourne, Australia. Electronic address: david.clark@austin.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH